Scott E Jordan1, Heba Saad2, Alex Sanchez Covarrubias1, John Siemon1, J Matt Pearson1, Brian M Slomovitz3, Marilyn Huang1, Andre Pinto2, Matthew Schlumbrecht1, Sophia Hl George4. 1. Sylvester Comprehensive Cancer Center, University of Miami, Division of Gynecologic Oncology, USA. 2. University of Miami Miller School of Medicine, Department of Pathology, USA. 3. Sylvester Comprehensive Cancer Center, University of Miami, Division of Gynecologic Oncology, USA; Dr. Slomovitz present affiliation: Broward Health, Florida International University Wertheim College Of Medicine, USA. 4. Sylvester Comprehensive Cancer Center, University of Miami, Division of Gynecologic Oncology, USA. Electronic address: Sophia.george@med.miami.edu.
Abstract
OBJECTIVE: Mutations in the MAP kinase pathway (KRAS, NRAS, BRAF) are common in low grade serous ovarian carcinoma (LGSOC). The effect of these and other mutations on RNA transcription in this disease is poorly understood. Our objective was to describe patterns of somatic mutations and gene transcription in a racially diverse population with LGSOC. METHODS: Utilizing an institutional tumor registry, patients with LGSOC were identified and charts were reviewed. RNA was extracted from available tumor tissue. Commercial tumor profiling results were analyzed with PanCancer pathway nanoString mRNA expression data. Along with nanoString n-Solver software, Chi-squared, Fishers Exact, and Cox proportional hazards models were used for statistical analysis, with significance set at p < 0.05. RESULTS: 39 patients were identified-20% Black, 43% Hispanic, and 36% non-Hispanic White. 18 patients had commercial somatic DNA test results, and 23 had available tumor tissue for RNA extraction and nanoString analysis. The most common somatic alterations identified was KRAS (11 patients, 61%), followed by ERCC1 and TUBB3 (9 each, 50%). KRAS mutations were less common in smokers (14.3% vs 90.9%, p = 0.002). RNA expression analysis demonstrated a greater than two-fold decrease in expression of HRAS in tumors from older patients (p = 0.04), and a greater than two-fold decrease in the expression of HRAS in recurrent tumors (p = 0.007). No significant differences were seen in somatic testing results, RNA expression analysis, or progression free survival between different racial and ethnic cohorts. CONCLUSIONS: Somatic deficiencies in ERCC1, TUBB3, and KRAS are common in LGSOC in a population of minority patients. HRAS demonstrates decreased expression in tumors from older patients and recurrent tumors.
OBJECTIVE: Mutations in the MAP kinase pathway (KRAS, NRAS, BRAF) are common in low grade serous ovarian carcinoma (LGSOC). The effect of these and other mutations on RNA transcription in this disease is poorly understood. Our objective was to describe patterns of somatic mutations and gene transcription in a racially diverse population with LGSOC. METHODS: Utilizing an institutional tumor registry, patients with LGSOC were identified and charts were reviewed. RNA was extracted from available tumor tissue. Commercial tumor profiling results were analyzed with PanCancer pathway nanoString mRNA expression data. Along with nanoString n-Solver software, Chi-squared, Fishers Exact, and Cox proportional hazards models were used for statistical analysis, with significance set at p < 0.05. RESULTS: 39 patients were identified-20% Black, 43% Hispanic, and 36% non-Hispanic White. 18 patients had commercial somatic DNA test results, and 23 had available tumor tissue for RNA extraction and nanoString analysis. The most common somatic alterations identified was KRAS (11 patients, 61%), followed by ERCC1 and TUBB3 (9 each, 50%). KRAS mutations were less common in smokers (14.3% vs 90.9%, p = 0.002). RNA expression analysis demonstrated a greater than two-fold decrease in expression of HRAS in tumors from older patients (p = 0.04), and a greater than two-fold decrease in the expression of HRAS in recurrent tumors (p = 0.007). No significant differences were seen in somatic testing results, RNA expression analysis, or progression free survival between different racial and ethnic cohorts. CONCLUSIONS:Somatic deficiencies in ERCC1, TUBB3, and KRAS are common in LGSOC in a population of minority patients. HRAS demonstrates decreased expression in tumors from older patients and recurrent tumors.
Authors: Kathleen M Schmeler; Charlotte C Sun; Diane C Bodurka; Michael T Deavers; Anais Malpica; Robert L Coleman; Pedro T Ramirez; David M Gershenson Journal: Gynecol Oncol Date: 2007-12-26 Impact factor: 5.482
Authors: Brian Slomovitz; Charlie Gourley; Mark S Carey; Anais Malpica; Ie-Ming Shih; David Huntsman; Amanda N Fader; Rachel N Grisham; Matthew Schlumbrecht; Charlotte C Sun; Jane Ludemann; Gail Austin Cooney; Robert Coleman; Anil K Sood; Haider Mahdi; Kwong K Wong; Allan Covens; David M O'Malley; Fabrice Lecuru; Lauren P Cobb; Thomas A Caputo; Taymaa May; Marilyn Huang; John Siemon; Marta Llauradó Fernández; Isabelle Ray-Coquard; David M Gershenson Journal: Gynecol Oncol Date: 2020-01-20 Impact factor: 5.482
Authors: K Takezawa; I Okamoto; W Okamoto; M Takeda; K Sakai; S Tsukioka; K Kuwata; H Yamaguchi; K Nishio; K Nakagawa Journal: Br J Cancer Date: 2011-04-12 Impact factor: 7.640
Authors: Xi Chen; Natasha G Deane; Keeli B Lewis; Jiang Li; Jing Zhu; M Kay Washington; R Daniel Beauchamp Journal: PLoS One Date: 2016-05-13 Impact factor: 3.240
Authors: Tarek M A Abdel-Fatah; Reem Ali; Maaz Sadiq; Paul M Moseley; Katia A Mesquita; Graham Ball; Andrew R Green; Emad A Rakha; Stephen Y T Chan; Srinivasan Madhusudan Journal: Cancers (Basel) Date: 2019-08-10 Impact factor: 6.639
Authors: Efrat L Amitay; Prudence R Carr; Lina Jansen; Wilfried Roth; Elizabeth Alwers; Esther Herpel; Matthias Kloor; Hendrik Bläker; Jenny Chang-Claude; Hermann Brenner; Michael Hoffmeister Journal: Br J Cancer Date: 2020-03-30 Impact factor: 7.640